WFH Humanitarian Aid Program

The lack of access to care and treatment in developing countries is an urgent and important public health challenge, as the cost of products to treat is prohibitively expensive for the majority of those affected with a bleeding disorder. The WFH is leading the effort to change this lack of access in developing countries by providing consistent and predictable access to treatment for all.

462,000,000+ 90 15,000+

160,000,000+ 60 16,189+


Visionary Contributors Contributors
Sanofi Genzyme CSL Behring
Sobi GC Pharma
  F. Hoffmann-La Roche Ltd.

The visionary contribution from Sanofi Genzyme and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015-2020). Sanofi Genzyme and Sobi also make ongoing substantial financial contributions to support the logistics of product delivery and training of providers and patients in humanitarian aid countries. Furthermore, the eight-year commitment (2014-2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009-2018) from CSL Behring for a total of 22 million IUs, the three-year agreement (2017-2019) with GC Pharma for 6 million IUs, and Roche, as a new donor, with a 5 year commitment (2019-2024) will provide products for prophylactic treatment, allowing for a more predictable and sustainable flow of humanitarian aid donations to the global community.

With increased multi-year donations and a steady flow of treatment products to the WFH network, it will be possible for people with bleeding disorders in the developing world have continued access to treatment for emergency situations, acute bleeds, corrective surgeries, and also prophylaxis for young children.

The WFH Humanitarian Aid Program also provides a range of integrated care development training programs to ensure the local infrastructure and medical expertise are available to optimize and appropriately use donated products.


Haemophilia Journal article details WFH Humanitarian Aid Program achievements

In “First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries” (G. F. Pierce et al, Haemophilia. 2018;24:229-235) readers have the chance to learn about the achievements of the WFH Humanitarian Aid Program in 2016—a year after the program’s scope was expanded. Along with contributions by WFH staff and volunteers, Glenn Pierce, MD, PhD, WFH Vice-President Medical, explores the situation in recipient countries before the expansion of this program and highlights how these countries could now respond to the treatment needs more effectively due to the increased predictability of donations. To read the full article, please click here.

Latest news on the WFH Humanitarian Aid Program  

The WFH talks to members of our global bleeding disorders community about the impact of, and the need for, the Humanitarian Aid Program during the 2016 World Congress. 

For more information about WFH humanitarian aid, contact us at

Charitable solicitations for the common purposes of WFH and WFH USA within the U.S. are conducted through WFH USA, a 501(c)3 affiliated entity.

Updated April 2019